Blog
RSS FeedPosted by Michael Wonder on 14 Oct 2016
NICE publishes draft guidance on the use of Opdivo by patients with NSCLC
14 October 2016 - NICE has published draft guidance on the use of Opdivo (nivolumab) by patients with lung cancer. ...
Posted by Michael Wonder on 13 Oct 2016
FY 2016 generic approvals by FDA: a new record under GDUFA
12 October 2016 - The US FDA published final Fiscal Year 2016 abbreviated new drug application (ANDA) approvals earlier this ...
Posted by Michael Wonder on 12 Oct 2016
Health Canada greenlights MendeliKABS for the commercialisation of PrMDK-nitisinone
11 October 2016 - MendeliKABS is proud to announce that Health Canada has approved MDK-Nitisinone medication for the treatment of hereditary ...
Posted by Michael Wonder on 12 Oct 2016
Decision to award sole supply of venlafaxine
12 October 2016 - PHARMAC is pleased to announce a decision to award a sole supply arrangement for venlafaxine hydrochloride ...
Posted by Michael Wonder on 11 Oct 2016
NICE publishes draft guidance on the use of Otezla on the NHS
11 October 2016 - NICE has published draft guidance on the use of Otelza (apremilast) on the NHS by patients ...
Posted by Michael Wonder on 11 Oct 2016
People with an advanced form of thyroid cancer now able to benefit from Lenvima (lenvatinib mesylate) in Scotland
10 October 2016 - Patients in England denied access to lenvatinib mesylate due to administrative delays. ...
Posted by Michael Wonder on 11 Oct 2016
Multi-product proposal involving nine pharmaceuticals
11 October 2016 - PHARMAC is seeking feedback on a proposal to fund three new treatments, widen access to three ...
Posted by Michael Wonder on 11 Oct 2016
Decision regarding funding of the HIV treatments dolutegravir (Tivicay) and abacavir sulphate with lamivudine (Kivexa)
11 October 2016 - PHARMAC is pleased to announce that the approval of an agreement with GlaxoSmithKline for the funding ...
Posted by Michael Wonder on 10 Oct 2016
Life-extending lung cancer drug approved for use in Scotland
10 October 2016 - Scotland has become the first part of the UK to approve a new life-extending treatment for ...
Posted by Michael Wonder on 10 Oct 2016
SMC - October 2016 decisions
10 October 2016 - New treatments for thyroid cancer and lung cancer among five medicines accepted for routine use by ...
Posted by Michael Wonder on 10 Oct 2016
U.S. FDA approves Carnexiv (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations
7 October 2016 - U.S. FDA approves Carnexiv (carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations. ...
Posted by Michael Wonder on 09 Oct 2016
NICE backs use of Forxiga in triple therapy for diabetes
7 October 2016 - NICE has now published final draft guidelines endorsing NHS use of AstraZeneca's Forxiga for treating type ...
Posted by Michael Wonder on 06 Oct 2016
FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
5 October 2016 - Fourteenth breakthrough therapy designation for Roche medicines. ...
Posted by Michael Wonder on 06 Oct 2016
Wound care decision points to future direction of devices work
6 October 2016 - PHARMAC is entering a new phase of its national hospital medical device contracting, as it implements ...
Posted by Michael Wonder on 06 Oct 2016
AbbVie's new oral therapy Venclexta now available for Canadians with a difficult-to-treat blood cancer
5 October 2016 - Health Canada's approval of Venclexta reinforces AbbVie's growing position in hematologic oncology. ...